| atezolizumab based treatment |
| atezolizumab plus bevacizumab | atezolizumab plus cabozantinib |
mHCC - (neo)adjuvant (NA) 3 | | |
mHCC - 1st line (L1) 10 | | |
mHCC - 2nd line (L2) 2 | | |
Comparator:
vs Standard of Care (SoC); vs sorafenib;
Risk of bias:
low;
some concerns;
high;
NA;